A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function

ConclusionOverall, we propose that TIGIT-based CSR can substantially enhance T-cell function and thus contribute to the improvement of engineered T cell-based immunotherapy.

http://link.springer.com/10.1186/s40425-019-0721-y

Source: Journal for Immunotherapy of Cancer - September 8, 2019 Category: Cancer & Oncology Source Type: research